Nimotuzumab: Phase III discontinued

In April, Daiichi Sankyo discontinued a double-blind, placebo-controlled, Japanese Phase III trial evaluating IV nimotuzumab with concurrent chemoradiotherapy as first-line treatment of unresectable and locally advanced squamous cell lung cancer. The company said the decision was based on a recommendation from an independent DMC, which observed safety issues in patients receiving a combination of cisplatin, vinorelbine, radiotherapy and nimotuzumab. Nimotuzumab has Orphan Drug designation in the U.S. and Europe to treat glioma. ...